Prediction of clinical pharmacokinetics of AMG 181, a human anti-\( \alpha_4\beta_7 \) monoclonal antibody for treating inflammatory bowel diseases

Hong Li\(^1\), Kathleen Köck\(^1\), John A. Wisler\(^2\), William A. Rees\(^3\), Peter J. Prince\(^1\), Kai O. Reynhardt\(^3\), Hailing Hsu\(^4\), Zhigang Yu\(^5,a\), Dominic C. Borie\(^6,a\), David H. Salinger\(^1,a\) & Wei-Jian Pan\(^1,a\)

\(^1\)Pharmacokinetics and Drug Metabolism, Amgen Inc., Seattle, Washington
\(^2\)Comparative Biology and Safety Sciences, Amgen Inc., Thousand Oaks, California
\(^3\)Medical Sciences, Amgen Inc., Seattle, Washington
\(^4\)Inflammation Discovery Research, Amgen Inc., Thousand Oaks, California
\(^5\)Medical Sciences, Amgen Inc., Thousand Oaks, California
\(^6\)Global Development, Amgen Inc., South San Francisco, California

Keywords
AMG 181, anti-\( \alpha_4\beta_7 \), cell trafficking, Crohn’s disease, gut homing, human antibody, inflammatory bowel diseases, PK/PD predictions, T cells, ulcerative colitis, \( \alpha_4\beta_7 \) integrin

Abstract
The purpose of this study was to predict a safe starting dose of AMG 181, a human anti-\( \alpha_4\beta_7 \) antibody for treating inflammatory bowel diseases, based on cynomolgus monkey pharmacokinetic (PK) and pharmacodynamic (PD) data. A two-compartment model with parallel linear and target-mediated drug disposition for AMG 181 PK in cynomolgus monkey was developed. The estimated parameters were allometrically scaled to predict human PK. An \( E_{\text{max}} \) PD model was used to relate AMG 181 concentration and free \( \alpha_4\beta_7 \) receptor data in cynomolgus monkey. AMG 181 clinical doses were selected based on observed exposures at the no adverse effect level of 80 mg\( \cdot \)kg\(^{-1} \) in monkeys, the predicted human exposures, and AMG 181 concentration expected to produce greater than 50% \( \alpha_4\beta_7 \) receptor occupancy in humans. The predicted human AMG 181 clearance and central volume of distribution were 144 mL\( \cdot \)day\(^{-1} \) and 2900 mL, respectively. The estimated \( EC_{50} \) for free \( \alpha_4\beta_7 \) receptor was 14 ng\( \cdot \)mL\(^{-1} \). At the 0.7 mg starting dose in humans, the predicted exposure margins were greater than 490,000 and AMG 181 concentrations were predicted to only briefly cover the free \( \alpha_4\beta_7 \) receptor \( EC_{10} \). Predictions for both \( C_{\text{max}} \) and AUC matched with those observed in the first-in-human study within the 7 mg subcutaneous to 420 mg intravenous dose range. The developed model aided in selection of a safe starting dose and a pharmacological relevant dose escalation strategy for testing of AMG 181 in humans. The clinically observed human AMG 181 PK data validated the modeling approach based on cynomolgus monkey data alone.

Abbreviations
AUC, area under the concentration–time curve; CD, Crohn’s disease or cluster of differentiation; CHO, Chinese Hamster Ovary cells; CL, Clearance; \( C_{\text{max}} \), maximum observed concentration; \( EC_{50} \), concentration at half-maximal effect; ECL, electrochemiluminescence; F1, subcutaneous bioavailability; GLP, good laboratory practice; HEK, human embryonic kidney cells; IBD, inflammatory bowel diseases; IgG, immunoglobulin G; IV, interindividual variability; IV, intravenous(ly); JC virus, John Cunningham polyomavirus; \( K_a \), absorption rate constant; \( K_D \), dissociation constant; \( K_{\text{int}} \), internalization rate constant; \( K_{\text{m}} \), Michaelis–Menten constant; \( K_{\text{ss}} \), quasi-steady-state constant; LLOQ, lower limit of quantification; MAdCAM-1,
mucosal addressin cell adhesion molecule 1; M-M, Michaelis–Menten; NIH, National Institutes of Health; PBMC, peripheral blood mononuclear cells; PD, pharmacodynamics(s); PK, pharmacokinetic(s); PML, progressive multifocal leukoencephalopathy; QE, quasi-equilibrium; QSS, quasi-steady state; \( R_{\text{true}} \), total receptor concentration; SC, subcutaneous(ly); TMDD, target-mediated drug disposition; UC, ulcerative colitis; \( V_c \), central volume of distribution; \( V_{\text{max}} \), maximum nonlinear elimination rate; VPC, visual predictive check.

**Introduction**

Crohn’s disease (CD) and ulcerative colitis (UC) are the two major types of inflammatory bowel diseases (IBD). Currently, anti-tumor necrosis factor agents (anti-TNFs) are the main class of approved biologics for treating CD and UC. However, there is a need for development of new therapeutics for those patients who do not respond or have developed tolerance to anti-TNFs after initial treatment. Therapies that block the influx of pro-inflammatory cells into the intestinal mucosa through integrin-mediated leukocyte tethering, rolling, and arrest (Hynes 2002) have gained attention in recent years.

Preclinical animal models have demonstrated the roles and benefits of blocking lymphocyte intestinal homing through antagonism of integrin \( \alpha_4 \beta_7 \) (Hesterberg et al. 1996; Fedyk et al. 2012; Pan et al. 2012), integrin \( \beta_7 \) (Wagner et al. 1996; Apostolaki et al. 2008; Stefanich et al. 2011), and integrin \( \alpha_4 \beta_7 \) ligand MAdCAM-1 (Picarella et al. 1997; Pullen et al. 2009). There are currently several IBD treatments targeting leukocyte migration and adhesion in clinical development, including vedolizumab (anti-\( \alpha_4 \beta_7 \)), etrolizumab (anti-\( \beta_7 \)), PF-00547659 (anti-MAdCAM-1), GSK-1605786 (anti-CCR9), and AJM300 (anti-\( \alpha_4 \)) (Thomas and Baumgart 2012; Lobaton et al. 2014). Natalizumab (anti-\( \alpha_4 \)) has been approved in the United States for the treatment of CD (Sandborn et al. 2005; Targan et al. 2007) and vedolizumab has shown clinical benefits in treating both CD and UC (Feagan et al. 2005, 2008; Parikh et al. 2011).

Natalizumab is a humanized immunoglobulin (Ig) G4 antibody targeting \( \alpha_4 \) and is thus antagonistic against both \( \alpha_4 \beta_1 \) for treating relapsing and remitting forms of multiple sclerosis (Polman et al. 2006) and \( \alpha_4 \beta_7 \) for treating CD (Sandborn et al. 2005). Natalizumab-mediated inhibition of trafficking of \( \alpha_4 \beta_1 \)-expressing leukocyte to the central nervous system through pan-\( \alpha_4 \) inhibition may be linked to progressive multifocal leukoencephalopathy (PML) caused by reactivation of latent human John Cunningham (JC) polyomavirus infection (Berger and Koralnik 2005). Additionally, natalizumab as well as vedolizumab (IgG1) are humanized antibodies and have shown greater than 10% immunogenicity in IBD patients leading to diminishing clinical efficacy (Feagan et al. 2005, 2008; Sandborn et al. 2005; Parikh et al. 2011).

AMG 181, a human monoclonal IgG2 antibody that binds specifically to the \( \alpha_4 \beta_7 \) integrin, has been designed to reduce or eliminate the immunogenic response and also avoids targeting the \( \alpha_4 \beta_1 \)-expressing leukocytes implicated in the occurrence of PML reported previously in natalizumab-treated patients. Comprehensive investigational results from AMG 181 in vitro pharmacology experiments and in vivo pharmacokinetic and toxicology studies have been published previously (Pan et al. 2013).

Several recent publications have summarized methods for the first-in-human (FIH) dose estimation (Gibbs 2010; Chen et al. 2012; Zou et al. 2012). Here, a quantitative translation of AMG 181 in vitro and in vivo pharmacology from cynomolgus monkeys to humans is presented that uses 70% and 90% levels of \( \alpha_4 \beta_7 \) receptor occupancy to guide the selection of a safe starting dose and pharmacologically relevant single and multiple dose escalation schemes for Phase 1 clinical trials in healthy volunteers and IBD subjects (www.clinicaltrials.gov, study identifiers NCT01164904 and NCT01290042). Comparison with the clinical PK from the single-dose Phase 1 study (Pan et al. 2014) validated our modeling predictions.

**Materials and Methods**

**In vitro pharmacology studies**

AMG 181 (~144 kD) was manufactured at Amgen Inc. (Thousand Oaks, CA) by expression in a Chinese hamster ovary (CHO) cell line (Hsu et al. 2010). Results from in vitro pharmacology studies including \( \alpha_4 \beta_7 \) target receptor occupancy on CD4+ T-cell subsets, including central memory, effector memory, and naive T, have been reported previously (Pan et al. 2013).

**In vivo studies in cynomolgus monkeys**

Male and female cynomolgus monkeys (Macaca fascicularis), ranging from 2.1 to 6.4 kg, were cared for in accordance with the Guide for the Care and Use of Laboratory Animals, 8th Edition (National Research Council US 2011). Animals were socially housed at an indoor, AAALAC, Intl-accredited facility in species-specific housing. All research protocols were approved by the Institutional Animal Care and Use Committee. Animals were
fed a certified pelleted primate diet (PMI #5048, Richmond, IN) daily in amounts appropriate for the age and size of the animals, and had ad libitum access to water (municipality tap water processed through a reverse osmosis filter and passed through ultraviolet light treatment) via automatic watering system/water bottle. Animals were maintained on a 12:12 h light:dark cycle in rooms at 18–29°C (30–70% humidity) and had access to enrichment opportunities (small bits of fruit, cereal, or other treats). All animals were negative for simian retrovirus.

Cynomolgus monkeys were assigned to treatment groups for two single-dose PK/PD Studies A and C, a two-dose (2-weekly doses) toxicology Study B, a 3-month (13-weekly doses; Study D), and a 6-month (24-weekly doses; Study E) Good Laboratory Practice (GLP) toxicology study (Table 1). Pre- and postdose blood samples were collected for PK/PD and immunogenicity assessments. Postdose observations in toxicology studies were conducted to assess the safety of AMG 181. PK samples from the PK/PD studies and the non-GLP toxicology study were analyzed for AMG 181 using an electrochemiluminescence (ECL) immunoassay with a lower limit of quantification (LLOQ) of 2 ng/mL. The GLP toxicology study used an ECL immunoassay with a LLOQ of 20 ng/mL.

Serum samples were analyzed for anti-AMG 181-specific antibodies (antidrug antibodies; ADAs) using a validated immunoassay with a lower limit of detection (LLRD) of 20 ng/mL rabbit anti-AMG 181 polyclonal antibody in neat pooled cynomolgus monkey serum. Samples with values greater than the predefined assay-specific cut point ranging from 1.08 to 1.14 based on the signal-to-noise ratio (fold difference in the anti-AMG 181-specific antibodies assay signal of samples or positive controls relative to the assay background assessed by the negative control) were defined as ADA positive.

Table 1. Studies in cynomolgus monkeys used for modeling.

| Study | Description | N  | Groups | Treatments |
|-------|-------------|----|--------|------------|
| A     | Single-dose PK/PD | 18 males | 6 groups; 3/group | Vehicle control IV; 0.01, 0.1, 0.3, and 3 mg/kg AMG 181 IV; 3 mg/kg AMG 181 SC |
| B     | Two-dose Non-GLP Toxicology | 12 males 12 females | 3 groups; 4/sex/group | Vehicle control SC QW; 0.5 and 80 mg/kg AMG 181 SC QW |
| C     | Single-dose PK/PD | 18 males | 3 groups; 6/group | Vehicle control IV; 9 mg/kg AMG 181 IV; 9 mg/kg AMG 181 SC |
| D     | Three-month GLP Toxicology | 30 males 30 females | 5 groups; 6/sex/group | Vehicle control SC QW; 5, 20, or 80 mg/kg SC QW; 80 mg/kg IV QW |
| E     | Six-month GLP Toxicology | 22 males 22 females | 3 groups; 6-8/sex/group | Vehicle control SC QW; 20 or 80 mg/kg SC QW |

IV, intravenous; SC, subcutaneous; PK, pharmacokinetics; PD, pharmacodynamics; TK, toxicokinetics; QW, once-weekly.

AMG 181 PK data for modeling

PK data were collected from a total of 119 monkeys (73 males and 46 females) actively treated with AMG 181 for up to 420 days after the first dose, with 86 receiving SC and 33 receiving IV dose(s). The median body weight of the monkeys was 2.8 kg (mean: 3.43 kg; range: 2.1–6.4 kg). In all five studies, anti-AMG 181 antibodies or immunogenic response was observed in a majority of the monkeys, except for those dosed 80 mg·kg\(^{-1}\) SC or IV. In many cases, the presence of anti-AMG 181 antibodies clearly impacted the PK. Data point exclusion was based on a two-step process: In a first step, candidates for exclusion were identified based on ADA positivity. In the second step, only data points where PK was also visually impacted were excluded (Fig. S2). This approach resulted in removal of 120 out of the 1743 (6.88%) available PK data points. The remaining 1623 AMG 181 concentration–time values were used for compartmental PK modeling.

Compartmental modeling of AMG 181 PK data

PK structural models

Visual inspection of the individual cynomolgus monkey PK data showed an initial distribution phase after IV and a terminal nonlinear elimination phase after both IV and SC administration. Individual PK data were simultaneously fit to a two-compartment PK model with target-mediated drug disposition (TMDD) (Mager and Jusko 2001) using quasi-steady-state (QSS) approximation (Gibiansky et al. 2008) or quasi-equilibrium (QE) approximation (Mager and Krzyzanski 2005). A two-compartment PK model with parallel linear and nonlinear Michaelis–Menten (M-M) was also fitted, but this model was not found superior to the simplified TMDD models (data for
PK variability models

Values for interindividual variability (IIV) of $K_A$, $CL$, $V_c$, and $R_{tot}$ were estimated assuming lognormal distribution. The residual variability was assumed to have a mixture of proportional plus additive distribution.

Estimation method, diagnosis, and validation

PK datasets and results were constructed, tabulated, and plotted using S-PLUS® (Version 8.2, November 2010; TIBCO Software Inc., Palo Alto, CA) or SigmaPlot (Version 12.5; Systat Software, Inc., Chicago, IL, USA). Modeling of the monkey PK data and simulation of the human PK profiles were performed using nonlinear mixed-effects modeling using NONMEM®, Version 7.2 with gfortran FORTRAN compiler (Beal et al. 2009).

Allometric scaling and simulation of human PK

For the prediction and simulation of human PK, the structural PK models developed for cynomolgus monkeys (median observed body weight of 2.8 kg) were assumed to also describe AMG 181 disposition in humans (assumed median body weight of 70 kg) with parameters allometrically scaled (Dong et al. 2011). The AMG 181 CL and $V_c$ values in human were determined from those in cynomolgus monkey by scaling by body weight ratio with exponents of 0.75 and 1, respectively. The distribution rate constants ($K_{12}$ and $K_{21}$) were scaled with an exponent of $-0.25$. The $K_d$ constant was fixed at 0.031 nmol/L, the EC$_{50}$ value of AMG 181 binding to monkey primary T cells in vitro.

The first-order conditional estimation method with interaction (FOCE INTERACTION) was used to estimate the population PK parameters. Importance sampling method, with $EONLY = 1$ ("evaluation only"), was applied to facilitate obtaining the standard error of model parameters.

Model selection was guided by visual inspection of goodness-of-fit plots, parameter estimate precision/plausibility, and comparison of objective function values. All parameter estimates were reported with the relative standard error of the estimates (%SE). Internal model validation was carried out by visual predictive check (VPC) plots; four hundred datasets were simulated based on final parameter estimates and the estimated 10th, 50th, and 90th percentiles of the simulated AMG 181 concentration–time profiles were plotted against the observed data.

AMG 181 PD data and modeling

Study A was a dedicated PK/PD study in cynomolgus monkeys, where AMG 181 occupancy of free $\alpha_4\beta_7$ on CD4+ T cell and its subsets were evaluated ex vivo. Mean fluorescence intensity (MFI) readings of free $\alpha_4\beta_7$ and the time-matched AMG 181 concentrations in serum were used for curve fitting using an $E_{max}$ model:

$$E = E_a (1 - E_{max} C/(EC_{50} + C)),$$

where the effect ($E$ or MFI) was estimated through baseline ($E_0$), maximum effect ($E_{max}$), AMG 181 concentration at half-maximal effect ($EC_{50}$), and AMG 181 concentration ($C$). Subsequent calculations for $EC_{75}$, $EC_{90}$, and $EC_{99}$ and the AMG 181 concentrations at 75%, 90%, and 99% maximal effect, respectively, were carried out based on the $E_{max}$ model. Results from Studies B–E were not used for PD modeling due to high data variability and limited availability (especially GLP studies).
binding potencies to human primary T cells. Other PK parameters including $K_a$, $F_1$, $R_{tot}$, and $K_{int}$ were assumed to be equivalent for cynomolgus monkeys and humans.

**Exposure margins and FiH dose selection**

The exposure margins were calculated based on the observed AMG 181 $C_{max}$ (4850 µg·mL$^{-1}$) and area under the concentration–time curve (AUC, 485,000 h·µg·mL$^{-1}$) values in cynomolgus monkeys at the no observed adverse effect level (NOAEL; Study D) of 80 mg·kg$^{-1}$ IV divided by the predicted human $C_{max}$ and AUC values.

AMG 181 doses for the FiH study were selected based on: (1) the exposure margins; the duration of serum AMG 181 concentration above 50–90% $x_4{7}^{7}$ receptor occupancy; and the maximum recommended starting dose (MRSD) in humans according to the United States Food and Drug Administration (US FDA) guidance (FDA 2005).

**Comparison of predicted versus observed AMG 181 PK in humans**

The predicted AMG 181 AUC and $C_{max}$ in humans were compared to the AMG 181 PK parameters observed in the FiH study with doses ranging from 7 mg SC to 420 mg IV. Data from the FiH study of AMG 181 have been reported separately (Pan et al. 2014).

**Results**

**Compartmental modeling of AMG 181 PK in cynomolgus monkeys**

In the final model, the individual AMG 181 concentration–time data for all cynomolgus monkeys from Studies A–E were simultaneously fit using a two-compartment TMDD QE PK model (Fig. 1). This model performed well for single and multiple dose administration with the exception of lowest single-dose cohort (0.01 mg·kg$^{-1}$ IV), where the model underpredicted the observed concentrations (Fig. 2). The diagnostic plots presented in Figure 3 suggest that the PK model characterized the observed concentration–time data well. Some divergence from the line of identity was observed at higher concentrations in the DV versus PRED plot. This deviation may have been due, in part, to the attempt to reconcile the PK from the 80 mg·kg$^{-1}$ IV and SC doses, where SC dosing resulted in higher exposure compared to the IV dose (Fig. S1A).

Table 2 summarizes the AMG 181 population parameters and IIV in cynomolgus monkeys estimated in the final model. The population PK parameter estimates as well as the IIVs were generally well estimated with relative standard error (%SE) of less than 30%. In Studies A, C, and D, where AMG 181 was administered both SC and IV, relative bioavailability after SC was estimated to be 80–96% via noncompartmental analysis. In our first PK modeling attempt, the SC bioavailability ($F_1$) was initially estimated to be close to 1 and was subsequently set to 1.0 (or 100%) to stabilize the model and to provide a conservative approach when the same assumption was also applied in prediction of human PK. No IIV on $F_1$ was estimated.

The estimated population central volume of distribution ($V_c$) was 116 mL, which is physiologically plausible for a typical 2.8 kg cynomolgus monkey (Davies and Morris 1993). Based on the typical PK parameters, the linear elimination half-life of AMG 181 was estimated to be 12 days. Since the target ($x_4{7}^{7}$) receptor concentrations were not available and few drug concentrations were measured at the terminal phase, $R_{tot}$ and $K_s$ could not be simultaneously estimated. Therefore, $K_s$ was fixed to 0.013 nmol/L, the $EC_{50}$ value of AMG 181 binding to $x_4{7}^{7}$ receptors on monkey primary T cells in vitro, in the final model and $R_{tot}$ was estimated relative to this assumption (Table 2).

Figure 4 shows the internal model validation carried out using visual predictive checks (VPC). With 400 datasets simulated based on final parameter estimates, the estimated medians and the two-sided 80% prediction intervals (10th, 50th, and 90th percentiles) of the simulated AMG 181 concentration–time profiles contained the observed PK data well, especially in light of the small sample sizes per dose group and over an 8000-fold dose range (0.01–80 mg·kg$^{-1}$).

**Modeling of AMG 181 PD in cynomolgus monkeys**

For Study A, individual observed free $x_4{7}^{7}$ receptor on total CD4$^+$ T cells (measured as MFI) versus AMG 181 concentration data is compared to the model fit in Figure 5. The estimated PD model parameters were 531 (MFI), 0.922, and 0.0140 ± 0.0082 µg·mL$^{-1}$ for $E_0$, $E_{max}$, and $EC_{50}$, respectively. Based on the model, the calculated values for $EC_{75}$, $EC_{90}$, and $EC_{99}$ are 0.042, 0.126, and 1.38 µg·mL$^{-1}$, respectively.

As a pharmacologic consequence of $x_4{7}^{7}$ occupancy, counts of total CD4$^+$ T cell and its subsets, including naive and central memory cell counts, were elevated due to the inhibition of their trafficking into the intestinal tissues. Because the CD4$^+$ T cell and its subset count data were sparse and highly variable in all studies, PD modeling attempts using cell count measures were not successful: qualitative assessments have been reported elsewhere (Pan et al. 2013).
Allometric scaling, simulation, and dose selection in humans

The estimated AMG 181 PK parameters in humans, determined through allometric scaling from parameters determined in cynomolgus monkeys, are presented in Table 3. These PK parameters (e.g., CL and $V_c$) are physiologically reasonable for kinetics of monoclonal antibodies in human (Davies and Morris 1993). Using these parameters, the AMG 181 concentration–time profiles were simulated under various single SC or IV dosing regimens or multiple SC dosing regimens (Fig. 6). The $EC_{50}$, $EC_{75}$, $EC_{90}$, and $EC_{99}$ values for AMG 181 occupancy of free $\alpha_4\beta_7$ receptors on CD4$^+$ T cell in humans were assumed to be the same as those estimated in monkeys and are given as reference concentration levels for the pharmacologic effect in Figure 6A. These levels were used to assess the duration of human AMG 181 concentration over various target saturation levels in designing the subsequent FIH study.

Based on our simulations, the estimated $C_{max}$ at the starting dose of 0.7 mg SC would be associated with approximately 10% of the maximum PD effect ($EC_{10}$), while the 21, 70, 210, and 420 mg doses were predicted to cover $EC_{90}$ for approximately 2, 3, 5, and 6 months, respectively (Fig. 6A). All four multiple dosing regimens were predicted to maintain AMG 181 concentration above $EC_{90}$ for 3–8 months (Fig. 6B).

The model-predicted AMG 181 $C_{max}$ and AUC values in humans, based on the simulated PK profiles, are presented in Figure 6, and the estimated exposure margins relative to the NOAEL of 80 mg·kg$^{-1}$ in cynomolgus...
monkeys are listed in Table 4. Based on these exposure ratios, a greater than 490,000-fold safety margin at the starting dose of 0.7 mg SC in healthy subjects was anticipated. This low starting dose of 0.7 mg was selected because it was predicted to only briefly cover the predicted EC10, in accordance with the Minimal Anticipated Biological Effect Level (MABEL, EMA 2007; Lowe et al. 2010; Yu et al. 2011) guidance by the European Medicines Agency (EMA). Also, based on the US FDA guidance on “Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers” (FDA 2005), the starting dose of 0.7 mg was approximately 1/260th of the calculated maximum recommended safe starting dose (MRSD). The MRSD was calculated to be 2.58 mg/[C1][C0]1 based on the body surface scaling with exponent 0.67, with an average body weight of 3 kg for monkeys and 60 kg (per MRSD FDA guidance) for humans, a NOAEL of 80 mg/[C1][C0]1 in monkeys, and a default safety factor of 10.

Comparison of predicted versus observed AMG 181 PK in humans

The observed AMG 181 Cmax and AUCinf values in the FIH study were well predicted based on scaling of cynomolgus monkey PK (Fig. 7). With the exception of lower doses (0.7 and 2.1 mg AMG 181), where Cmax and AUCinf were underpredicted, the observed human AMG 181 Cmax and AUCinf values were within twofold of the predicted values, consistent with what has previously been reported for allometric scaling of monoclonal antibody PK from cynomolgus monkey to human (Dong et al. 2011). Given the large exposure margins at the proposed FIH starting dose of 0.7 mg, this slight underprediction was not expected to have consequences for patient safety.

Table 2. AMG 181 PK parameter estimates in cynomolgus monkeys through simultaneous fitting of the individual AMG 181 concentration-time data using the two-compartment pharmacokinetic target-mediated drug disposition (TMDD) model with quasi-equilibrium (QE) approximation.

| PK parameter (unit) | Estimate (%SE) | IIV (%SE) |
|---------------------|----------------|-----------|
| Kₐ (day⁻¹)          | 0.846 (3.8)    | NE        |
| CL (mL·day⁻¹)       | 12.9 (5.9)     | 44.1 (20) |
| Vc (mL)             | 116 (7.9)      | 46.1 (17) |
| K₁₂ (day⁻¹)         | 0.617 (13)     | Fixed to 0|
| K₂₁ (day⁻¹)         | 0.877 (8.8)    | Fixed to 0|
| Kₐ (nmol·L⁻¹)       | Fixed to 0.013 | Fixed to 0|
| Rtot (nmol·L⁻¹)     | 9.18 (20)      | 180 (23)  |
| Kint (day⁻¹)        | 0.0215 (6.0)   | Fixed to 0|
| Correlation CL, Vc  | 0.642 (27)     |           |
| Proportional residual error (% CV) | 20.1 (1.9) | |
| Additive residual error SD (nmol·L⁻¹) | 1.11 (14) | |

CV, coefficient of variation; IIV, interindividual variability; NE, not estimated.
Prediction of AMG 181 PK/PD in Humans

H. Li et al.

Discussion and Conclusions

AMG 181 is a human monoclonal antibody that specifically targets intestinal-homing T cells and has been tested for pharmacological activity in vitro as well as for safety and PK/PD in vivo in the pharmacologically relevant species *M. fascicularis* (cynomolgus monkey) (Pan et al. 2014). This report presents a quantitative translational approach for the selection of a safe starting dose and pharmacologically relevant single and multiple dose esca-

![Figure 4. Visual predictive checks for the two-compartment TMDD QE PK model (by cohort): median predictions (solid lines) with 80% confidence intervals (10th and 90th percentiles; dashed lines). Symbols represent observed individual AMG 181 concentrations.](image)

![Figure 5. Individual observed free $\alpha_4\beta_7$ receptor on CD4+ T cells (expressed as mean fluorescence intensity (MFI) of the detecting antibody for the free $\alpha_4\beta_7$ receptor) versus AMG 181 concentrations (symbol). The line represents the $E_{max}$ PD model fitting of the observed data.](image)

| PK parameter (unit) | Human estimate |
|---------------------|----------------|
| $F_1$               | 1.0 (NS)       |
| $K_A$ (day$^{-1}$)  | 0.846 (NS)     |
| $CL$ (mL·day$^{-1}$)| 144            |
| $V_c$ (mL)          | 2900           |
| $K_{12}$ (day$^{-1}$)| 0.276         |
| $K_{21}$ (day$^{-1}$)| 0.392         |
| $K_d$ (nmol·L$^{-1}$)| 0.013 (NS)   |
| $R_{tot}$ (nmol·L$^{-1}$)| 9.18 (NS) |
| $K_{int}$ (day$^{-1}$)| 0.0215 (NS) |

NA, not applicable; NS, not scaled.
lation schemes for Phase 1 clinical trials in healthy volunteers and IBD subjects.

Based on visual inspection of the PK profiles in monkeys, AMG 181 disposition was dose- and concentration-dependent with typical linear clearance dominating at higher concentrations and nonlinear clearance dominating at low concentrations (<1 µg·mL⁻¹, ~7 nmol/L), likely due to saturable binding of AMG 181 to the target T-cell surface α4β7 receptors. To describe the parallel linear and nonlinear disposition, a TMDD model (Mager and Jusko 2001) was utilized and all individual monkey AMG 181 concentration–time data were fitted simultaneously.

AMG 181 binds to α4β7 receptor with high affinity with a dissociation constant (K_D = K_{off}/K_{on}) of 13 pmol·L⁻¹, suggesting that the drug–target association is faster than drug dissociation/distribution/elimination as well as elimination of the target and drug–target complex. In this case, the QSS approximation to TMDD, which assumes that drug–target complex rapidly approaches a quasi-steady state, is reasonable (Gibiansky and Gibiansky 2009). To overcome the difficulties with model parameter identifiability during model development, QSS model was further simplified to a QE model with K_{ss} = K_{d} = k_{off}/k_{on}.

During the model development, fitting of an empirical two-compartment PK model with parallel linear and nonlinear Michaelis–Menten (M-M) (Dong et al. 2011) elimination was also attempted. The M-M model fit similarly well to the high concentration data as did the TMDD models, but underpredicted concentrations at the terminal elimination phase where AMG 181 concentration were <0.1 µg·mL⁻¹ (Fig. S3A and B); consistent with what has been demonstrated by Gibiansky and Gibiansky (2009), Yan et al. (2010). The exception to this was for the lowest dose (0.01 mg·kg⁻¹·IV) where, unexpectedly, the M-M model provided a better model fit than QE TMDD model.

Figure 6. The two-compartment TMDD QE PK model predicted typical AMG 181 PK profiles in humans: (A) Single SC or IV dose (lines) overlaid with the observed mean (SD) data (symbols). (B) Three-monthly SC doses. E_{max} PD model predicted EC_{SO}, EC_{75}, EC_{50}, and EC_{99} values are presented to illustrate duration of AMG 181 concentration coverage over α4β7 receptor under each dosing regimen.
For our purpose, selection of either M-M model or QE TMDD model would have been sufficient to inform selection of FIH dosing. The TMDD QE model was chosen for further analyses and human dose predictions due to better overall model fit at clinically relevant doses.

Three factors posed challenges for better estimation of the AMG 181 PK across all concentrations and dose routes. First, AMG 181 is a human antibody and would unavoidably be immunogenic in monkeys, especially at lower concentrations. Second, only a limited number of monkeys were assigned to the recovery phase of the GLP studies. Both factors reduced the potential amount of PK data available for modeling the terminal elimination phase. Third, the relatively higher exposures observed after SC administration of 80 mg·kg⁻¹ AMG 181 than after IV administration of the same dose (Studies B and D vs. Study D, Fig. 2B) was undoubtedly a challenge for the model to reconcile. While this could potentially by explained by PK variability and small sample sizes, the observed differences could also have stemmed from non-neutralizing AMG 181 immune complex formation, which might have served as a reservoir (Chirmule et al. 2011) for AMG 181 through gradual disassociation and slow release of AMG 181 during the terminal elimination phase. The estimated slow half-life of ~32 days (= 0.693/Kint) for x4b7 receptor internalization may support this hypothesis and thus Kint might be a measure of both target receptor internalization and immune complex elimination.

The immunogenic response against AMG 181 clearly impacted specific PK data points, as illustrated for two representative animals in Figure 3. For this reason, 120 ADA-positive concentration–time points (representing less than 7% of total data) were excluded from model. This approach is conservative from a safety perspective as it resulted in higher estimated exposures in monkey and consequently in human. Additionally, since AMG 181 is a human IgG2, it is anticipated to carry less immunogenic potential in humans. Indeed, no ADAs were reported in the Ph1a study (Pan et al. 2014).

Dong et al. (2011) suggest that translation of nonlinear elimination to human might be improved by accounting for the between-species difference in target expression and binding. The lack of knowledge of x4b7 receptor abundance in cynomolgus monkeys and human necessitated the assumption that AMG 181 has the same in vivo pharmacology characteristics and x4b7 receptor abundance in cynomolgus monkeys and humans. This assumption was justified based on similar in vitro binding to primary T cells and blocking of x4b7:MAdCAM-1 binding on primary T cells and T-cell adhesion for cynomolgus monkey and human (Pan et al. 2013). Additionally, potential differences are not expected to affect patient safety due to the large observed safety margins.

The 75% and 90% receptor occupancy levels for natalizumab (anti-x4) and vedolizumab (anti-x4b7) have been reported to be related to the clinical efficacy in multiple sclerosis (FDA 2003) and IBD (Feagan et al. 2005, 2008). Therefore, the AMG 181 EC75 and EC90 values for x4b7 receptor occupancy were used as guides to aid the selection of AMG 181 dosing regimens in UC and CD clinical trials: 7, 21, 70, or 210 mg SC once every 1, 2, 3, or

| Proposed human dose | Dose (mg) | Route | PK parameter | Exposure ratio |
|---------------------|----------|-------|--------------|---------------|
| Single ascending dose study | | | | |
| 0.7 | 0.01 | SC | 0.0009 | 0.985 | 5520000 | 4920000 |
| 2.1 | 0.03 | SC | 0.004 | 3.81 | 1120000 | 1270000 |
| 7 | 0.1 | SC | 0.604 | 186 | 8030 | 2610 |
| 21 | 0.3 | SC | 3.48 | 1940 | 1390 | 250 |
| 70 | 1 | SC | 13.5 | 9500 | 358 | 51 |
| 210 | 3 | SC | 42.4 | 32,300 | 114 | 15 |
| 70 | 1 | IV | 22.7 | 9520 | 214 | 51 |
| 210 | 3 | IV | 70.8 | 32,300 | 69 | 15 |
| 420 | 6 | IV | 143 | 67,000 | 34 | 7 |

Multiple ascending dose study (Q4W × 3): after the 3rd dose

| | Dose (mg·kg⁻¹) | Route | PK parameter | Exposure ratio |
|---------------------|----------|-------|--------------|---------------|
| 7 | 0.1 | SC | 1.69 | 782 | 2870 | 620 |
| 21 | 0.3 | SC | 6.29 | 4120 | 771 | 118 |
| 70 | 1 | SC | 22.4 | 17,100 | 217 | 28 |
| 210 | 3 | SC | 68.4 | 55,300 | 71 | 9 |

The exposure ratios (margins) were calculated based on NOAEL of 80 mg·kg⁻¹ in cynomolgus monkeys (AUC_{max}: AUC within the 3rd dosing interval for the ascending multiple dose study).
4 months, respectively, would maintain AMG 181 concentration above EC90 within each dosing interval (Fig. 6B) and thus should be efficacious.

Analysis of the available clinical PK, safety and efficacy data from the ongoing studies have shown consistency with our prediction results as shown in Figure 7 (Pan et al. 2014). The predictions of Cmax and AUC were within twofold for single doses between 7 and 420 mg which is well accepted for large and small molecules (Hosea et al. 2009; Dong et al. 2011).

In conclusion, AMG 181 in vivo pharmacology from cynomolgus monkeys was successfully translated to humans using the described quantitative translation approach. The developed model was successfully employed to support the selection of a safe starting dose and pharmacologically as well as clinically relevant single and multiple dose escalation schemes for AMG 181 clinical trials in healthy volunteers and IBD subjects.

Acknowledgements

Financial support for this study and publication was provided by Amgen Inc. AMG 181 is being codeveloped by MedImmune, LLC, a wholly owned subsidiary of AstraZeneca plc., and Amgen Inc. and may be referred to as AMG 181 or MEDI7183.

The authors thank Amgen Therapeutic Discovery, Inflammatory Research, Medical Sciences, Pharmacokinetics and Drug Metabolism (PKDM), and Comparative Biology and Safety Sciences (CBSS) colleagues and Amgen contractors for their kind assistance in the antibody generation, production, and purification, the conduct of the studies, as well as data management and processing. The authors also thank Peiming Ma, Amgen Inc. for stimulating discussions and technical guidance on target-mediated disposition modeling.

Authorship Contributions

Li, Köck, Salinger, Pan, Wisler, Rees, Prince, Reynhardt, Hsu, Yu, and Borie participated in the research design. Pan, Wisler, Rees, Prince, and Reynhardt conducted the experiments. Hsu, Prince, Rees, and Reynhardt contributed new reagents or analytic tools. Li, Köck, Salinger, Rees, and Pan performed the data analysis. Li, Köck, Salinger, and Pan wrote or contributed to the writing of the manuscript.

Disclosures

AMG 181 is being codeveloped by MedImmune, LLC, a wholly owned subsidiary of AstraZeneca plc., and Amgen Inc. and may be referred to as AMG 181 or MEDI7183.

All authors are former or current employees and shareholders or contractors of Amgen Inc.

References

Apostolaki M, Manoloukos M, Roulis M, Wurbel MA, Muller W, Papadakis KA, et al. (2008). Role of beta7 integrin and the chemokine/chemokine receptor pair CCL25/CCR9 in modeled TNF-dependent Crohn’s disease. Gastroenterology 134: 2025–2035.

Beal SS, Boeckmann LB, Bauer RJ (2009). NONMEM user’s guides (1989–2009). ICON Development Solutions, Ellicott City, MD.

Berger JR, Koralnik IJ (2005). Progressive multifocal leukoencephalopathy and natalizumab–unforeseen consequences. N Engl J Med 353: 414–416.

Chen B, Dong JQ, Pan WJ, Ruiz A (2012). Pharmacokinetics/pharmacodynamics model-supported early drug development. Curr Pharm Biotechnol 13: 1360–1375.
Chirmule N, Jawa V, Meibohm B (2012). Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy. AAPS J 14: 296–302.

Davies B, Morris T (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10: 1093–1095.

Dong JQ, Salinger DH, Endres CJ, Gibbs JP, Hsu CP, Stouch BJ, et al. (2011). Quantitative prediction of human pharmacokinetics for monoclonal antibodies: retrospective analysis of monkey as a single species for first-in-human prediction. Clin Pharmacokinet 50: 131–142.

EMA (2007). Guideline on requirements for first-in-man clinical trials for potential high-risk medicinal products. Vol. 2012, 3/6/2007 edn. Committee for Medicinal Products for Human Use, http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002989.pdf.

FDA (2003). Natalizumab clinical pharmacology and biopharmaceutics review(s). Vol. 2012, US Food and Drug Administration.

FDA (2005). Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. Vol. 2012, 7/6/2005 edn. US Food and Drug Administration.

Feagan BG, Greenberg GR, Wild G, Fedorak RN, Pare P, McDonald JW, et al. (2005). Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 352: 2499–2507.

Feagan BG, Greenberg GR, Wild G, Fedorak RN, Pare P, McDonald JW, et al. (2008). Treatment of active Crohn’s disease with MLN0002, a humanized antibody to the alpha4 beta7 integrin. Clin Gastroenterol Hepatol 6: 1370–1377.

Fedyk ER, Wyant T, Yang LL, Csizmadia V, Burke K, Yang H, et al. (2012). Exclusive antagonism of the alpha(4) beta(7) integrin by vedolizumab confirms the gut-selectivity of this pathway in primates. Inflamm Bowel Dis 18: 2107–2119.

Gibbs JP (2010). Prediction of exposure-response relationships to support first-in-human study design. AAPS J 12: 750–758.

Gibiansky L, Gibiansky E (2009). Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics. Expert Opin Drug Metab Toxicol 5: 803–812.

Gibiansky L, Gibiansky E, Kakkar T, Ma P (2008). Approximations of the target-mediated drug disposition model and identifiability of model parameters. J Pharmacokinet Pharmacodyn 35: 573–591.

Hesterberg PE, Winsor-Hines D, Briskin MJ, Soler-Ferran D, Merrill C, Mackay CR, et al. (1996). Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7. Gastroenterology 111: 1373–1380.

Hosea NA, Collard WT, Cole S, Maurer TS, Fang RX, Jones H, et al. (2009). Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches. J Clin Pharmacol 49: 513–533.

Hsu H, Foltz I, Arora T, Jacobsen FW (2010). Alpha-4 beta-7 heterodimer specific (US 2010/0254975 A1). Office USP (ed) Vol. A1. Alexandria, VA, USA.

Hynes RO (2002). Integrins: bidirectional, allosteric signaling machines. Cell 110: 673–687.

Lobaton T, Vermeire S, Van Assche G, Rutgeert P (2014). Review article: anti-adhesion therapies for inflammatory bowel disease. Aliment Pharmacol Ther 39: 579–594.

Lowe PJ, Tannenbaum S, Wu K, Lloyd P, Sims J (2010). On setting the first dose in man: quantitating biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamic models. Basic Clin Pharmacol Toxicol 106: 195–209.

Mager DE, Jusko WJ (2001). General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn 28: 507–532.

Mager DE, Krzyzanski W (2005). Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Pharm Res 22: 1589–1596.

National Research Council US (2011). Guide for the care and use of laboratory animals. 8th ed. National Academies Press, Washington, DC.

Pan WJ, Lear SP, Patel SK, Prince PJ, Doherty DR, Tam CY, et al. (2012). Pharmacokinetics and pharmacodynamics in cynomolgus monkeys of AMG 181, a fully human anti-a4ß7 antibody for treating inflammatory bowel disease. J Crohn’s Colitis 6: pS14.

Pan WJ, Hsu H, Rees WA, Lear SP, Lee F, Foltz IN, et al. (2013). Pharmacology of AMG 181, a human anti-alpha4 beta7 antibody that specifically alters trafficking of gut-homing T cells. Br J Pharmacol 169: 51–68.

Pan WJ, Kock K, Rees WA, Sullivan BA, Evangelista CM, Yen M, et al. (2014). Clinical pharmacology of AMG 181, a gut-specific human anti-alpha beta monoclonal antibody, for treating inflammatory bowel diseases. Br J Clin Pharmacol Epub ahead of print.

Parikh A, Leach T, Wyant T, Scholz C, Sankoh S, Mould DR, et al. (2011). Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study. Inflamm Bowel Dis 18: 1470–1479.

Picarella D, Hurlbut P, Rottman J, Shi X, Butcher E, Ringler DJ (1997). Monoclonal antibodies specific for beta 7 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) reduce inflammation in the colon of scid mice reconstituted with CD45RBhigh CD4+ T cells. J Immunol 158: 2099–2106.
Polman CH, O’Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. (2006). A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354: 899–910.

Pullen N, Molloy E, Carter D, Syntin P, Clemo F, Fino-Kent D, et al. (2009). Pharmacological characterization of PF-00547659, an anti-human MAdCAM monoclonal antibody. Br J Pharmacol 157: 281–293.

Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, et al. (2005). Natalizumab induction and maintenance therapy for Crohn’s disease. N Engl J Med 353: 1912–1925.

Stefanich EG, Danilenko DM, Wang H, O’Byrne S, Erickson R, Gelzleichter T, et al. (2011). A humanized monoclonal antibody targeting the beta7 integrin selectively blocks intestinal homing of T lymphocytes. Br J Pharmacol 162: 1855–1870.

Targan SR, Feagan BG, Fedorak RN, Lasher BA, Panaccione R, Present DH, et al. (2007). Natalizumab for the treatment of active Crohn’s disease: results of the ENCORE Trial. Gastroenterology 132: 1672–1683.

Thomas S, Baumgart DC. (2012). Targeting leukocyte migration and adhesion in Crohn’s disease and ulcerative colitis. Inflammopharmacology 20: 1–18.

Wagner N, Lohler J, Kunkel EJ, Ley K, Leung E, Krissansen G, et al. (1996). Critical role for beta7 integrins in formation of the gut-associated lymphoid tissue. Nature 382: 366–370.

Yan X, Mager DE, Krzyzanski W (2010). Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models. J Pharmacokinet Pharmacodyn 37: 25–47.

Yu J, Karcher H, Feire AL, Lowe PJ (2011). From target selection to the minimum acceptable biological effect level for human study: use of mechanism-based PK/PD modeling to design safe and efficacious biologics. AAPS J 13: 169–178.

Zou P, Yu Y, Zheng N, Yang Y, Paholak HJ, Yu LX, et al. (2012). Applications of human pharmacokinetic prediction in first-in-human dose estimation. AAPS J 14: 262–281.

**Supporting Information**

Additional Supporting Information may be found in the online version of this article:

**Figure S1.** Diagnostic plots for the two-compartment TMDD QE PK model by study and cohort: (A) Observed versus population predicted concentrations. (B) Observed versus individual predicted concentrations. For study A, B, and C cohorts were combined for plotting purposes.

**Figure S2.** Concentration-time profiles in two representative animals to illustrate the ADA effect on PK. Red symbols and lines represent the mean (±SD) of the same dose group, black symbols indicate data of an individual subject; ADA-positive data points are depicted by x.

**Figure S3.** Simultaneous fit of the individual AMG 181 concentration-time data from all cynomolgus monkeys using the two-compartment MM PK model: (A) Single IV or SC dose and (B) 2-weekly, 13-weekly, or 24-weekly IV or SC doses. Symbols and dotted lines represent mean (±SD) observations. Solid lines represent the mean of model predicted individual concentration-time profiles in the respective cohort.